Open-label study to evaluate the use of imiquimod 5% cream for reducing postsurgical recurrence or persistence of basal cell carcinoma following excision by curettage.

Trial Profile

Open-label study to evaluate the use of imiquimod 5% cream for reducing postsurgical recurrence or persistence of basal cell carcinoma following excision by curettage.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2010

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2010 Additional lead trial center (Medicis Global Service Corporation) identified as reproted by ClinicalTrials.gov.
    • 15 Jul 2010 Companies added in association field as reported by ClinicalTrials.gov.
    • 14 Jul 2010 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top